Jim Cramer is ready for another chaotic week of earnings and recommended investors do their full homework before buying. » Read More
It's been four years since the Facebook IPO. Some stocks have done better in that time period.
Jim Cramer marked the anniversary of the market hitting an all-time high one year ago with an in-depth analysis of the Dow Jones.
Pfizer will buy Anacor Pharmaceuticals in a deal valued at $5.2 billion, for access to Anacor's non-steroidal topical gel to treat eczema.
U.S. stocks closed about 1 percent higher Monday, with energy stocks leading as oil prices hit fresh highs for the year so far.
The FMHR traders take their positions on four stocks making news today, including Barron's making a call on Regeneron.
Some of the names on the move ahead of the open.
Pfizer announces it is buying drugmaker Anacor Pharmaceuticals for $99.25 per share in cash.
CNBC's Sue Herera provides insight to a report regarding drugs used in lethal injections.
Pfizer announced controls on the distribution of its products to ensure that none are used in lethal injections, the New York Times reports.
Sanofi will nominate eight people to replace the board of Medivation, sources say.
Stephen DeNichilo, portfolio manager at Federated Kaufmann Funds and Mariann Montagne, senior investment analyst at Gradient Investments discuss what's with the blue chip blues.
The court did the right thing by shredding the Staples-Office Depot deal, a former FTC commissioner said Wednesday.
Mark Shafir, co-head of M&A at Citi, told CNBC why failed deals and regulatory scrutiny are giving clients pause.
Staples and Office Depot became the latest companies to abandon plans for a merger after facing scrutiny on antitrust grounds.
U.S. stocks closed more than 1 percent higher Tuesday, helped by weakness in the yen against the dollar and gains in oil prices.
Shares of Zoetis fell Tuesday following a New York Times report that billionaire hedge fund manager Bill Ackman is paring his stake.
Allergan reported a 48 percent rise in quarterly revenue, led by a strong performance by its branded drugs business.
His Pershing Square Capital has had a difficult year, particularly over its stake in Valeant, the drug company that has come under intense scrutiny.
Mergers and acquisitions activity may not pick up until President Barack Obama leaves the Oval Office, Robert Kindler says.
CNBC Pro highlights the top performing stocks this week and analyzes whether the good times will continue.